Day: March 21, 2023

Acadia Village Resort Licenses Zerify’s Secure Video Conferencing Platform

Written by Customer Service on March 21, 2023. Posted in Public Companies.

EDISON, N.J., March 21, 2023 (GLOBE NEWSWIRE) — Zerify Inc., (OTC PINK: ZRFY), the 22-year-old cybersecurity company focused on secure video conferencing & digital communications, announced today that Acadia Village Resort is licensing our Zerify Meet™ Secure Video Conferencing Platform. Acadia Village is a Premier Timeshare Resort located in Downeast Maine, a short distance from Acadia National Park and Bar Harbor. Jim Killam, Acadia Village’s resort director, says, “We use the Zerify Meet Secure Video Conferencing platform for all of our meetings held at the resort, in addition to quarterly board meetings. Security, ease of use, and the video quality are far superior than any of its competitors, along with their low cost. It makes going with Zerify Meet an extremely easy choice.” “We are thrilled that Jim at...

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase 1b in October 2022 ACTengine® IMA203 TCR-T clinical data update on all three ongoing IMA203 Phase 1b cohorts (Cohort A: 1st-gen monotherapy, Cohort B: combination with a checkpoint inhibitor, Cohort C: 2nd-gen monotherapy), and identification of most promising cohort to advance towards pivotal trials is planned for 2H 2023; prioritization of patient treatment with 1st and 2nd-generation monotherapy Expansion of cell therapy manufacturing capabilities with construction of an in-house GMP manufacturing facility for registration-directed and commercial production of ACTengine® TCR-T products expected to be operational in 2024 Phase 1 clinical...

Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP – – Presented interim data from natural history study, ILLUMINATE, at Company-hosted ALSP KOL event in December 2022 – – Appointed David Gray, Ph.D., as Chief Science Officer – WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent progress. “In 2022, we made considerable progress in advancing VGL101 and our small molecule TREM2 agonist program through significant clinical and preclinical milestones, respectively. We shared important data...

Bitfarms Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

– Mined 1,434 BTC in Q4 2022; 5,167 BTC in 2022;and 20,000+ BTC since inception through February 2023 –– Averaged direct cost of production of $10,000 per BTC in 2022-– Reported Q4 2022 net loss of $17 million and positive Adjusted EBITDA of $1 million –– Expects over 30% increase in hashrate to 6.0 EH/s with existing portfolio by year-end 2023 – This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated August 16, 2021 to its short form base shelf prospectus dated August 12, 2021. TORONTO, Ontario and BROSSARD, Québec, March 21, 2023 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ: BITF // TSX: BITF), a global Bitcoin vertically integrated company, reported its financial results for the fourth quarter and year ended December 31, 2022....

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

LONDON, March 21, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022.Full year 2022 revenues of $254.5 million. Q4 2022 revenue of $41.1 million compared to Q3 2022 revenue of $42.2 million; strong position in a changing COVID testing market. Increased our installed base by more than 1,500 Platform instruments, primarily in Europe, driven by new product sales in diabetes, inflammation, heart failure and respiratory disease. Demonstrating Platform consolidation strategy in UK and Germany. Commenced commercial shipments of heart failure tests in Europe. Working with the Independent Test Assessment Program (ITAP) established by the National Institutes of Health (NIH)...

Ducommun Incorporated Enters into Definitive Agreement to Acquire BLR Aerospace

Written by Customer Service on March 21, 2023. Posted in Mergers And Acquisitions.

Leading Provider of Proprietary Aerodynamic Systems that Enhance the Productivity, Performance and Safety of Rotary- and Fixed-Wing Aircraft SANTA ANA, Calif., March 21, 2023 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE:DCO) (“Ducommun” or the “Company”) today announced that it entered into a definitive securities purchase agreement (the “Transaction”) to acquire BLR Aerospace, LLC (“BLR”) on March 20,2023. The Transaction is subject to customary closing conditions and regulatory approval, and is expected to be completed during the second quarter of 2023. “I am delighted to welcome the team at BLR Aerospace to Ducommun as we continue to add proprietary engineered products to our portfolio,” said Stephen G. Oswald, chairman, president and chief executive officer of Ducommun Incorporated. “This is a first step in our commitment...

Crawford United Corporation Announces Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

Sales of $32.7 million for the quarter, an increase of 19.5% Sales of $127.8 million for the year, an increase of 22.6% Net Income of $6.6 million for the year and earnings per share of $1.89 EBITDA of $4.1 million for the quarter, an increase of 150.6% EBITDA of $13.7 million for the year, an increase of 27.1%CLEVELAND, March 21, 2023 (GLOBE NEWSWIRE) — Crawford United Corporation (OTC: CRAWA), a growth-oriented holding company serving diverse markets, today reported results for the three-month and twelve-month periods ended December 31, 2022. For the quarter ended December 31, 2022, sales were $32.7 million compared with $27.3 million in the same period last year, an increase of 19.5%. In this quarter, the Company recorded operating income of $2.7 million compared with operating income of $0.7 million in the same period last...

DSV, 1023 – SHARE BUYBACK IN DSV A/S

Written by Customer Service on March 21, 2023. Posted in Public Companies.

Company Announcement No. 1023On 2 February 2023, we initiated a share buyback programme, as described in Company Announcement No. 1013. According to the programme, the company will in the period from 2 February 2023 until 26 April 2023 purchase own shares up to a maximum value of DKK 2,500 million, and no more than 4,000,000 shares, corresponding to 1.83% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day Number of shares bought back Average transaction price Amount DKK Accumulated trading...

Form 8.3 – [DEVRO PLC 20 03 2023] – (CGWL)

Written by Customer Service on March 21, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree DEVRO PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early 2H 2023, and potential U.S. launch in 1H 2024 Announcement of data from ongoing chronic neutropenia Phase 2 trial and clarity on regulatory path forward planned in 2Q or 3Q 2023 Conference call to be hosted today at 9:00 a.m. ET BOSTON, March 21, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted key 2022 events and expected upcoming milestones. “We could not be more pleased with the progress we made in 2022...

Day: March 21, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals